Medigene Management
Management criteria checks 1/4
Medigene's CEO is Selwyn Ho, appointed in Jul 2022, has a tenure of 2.25 years. directly owns 0.42% of the company’s shares, worth CHF121.98K. The average tenure of the management team and the board of directors is 1.9 years and 7.2 years respectively.
Key information
Selwyn Ho
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 2.3yrs |
| CEO ownership | 0.4% |
| Management average tenure | 1.9yrs |
| Board average tenure | 7.2yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -€16m |
| Mar 31 2024 | n/a | n/a | -€16m |
| Dec 31 2023 | n/a | n/a | -€16m |
| Sep 30 2023 | n/a | n/a | -€23m |
| Jun 30 2023 | n/a | n/a | -€29m |
| Mar 31 2023 | n/a | n/a | -€19m |
| Dec 31 2022 | €612k | €157k | -€8m |
Compensation vs Market: Insufficient data to establish whether Selwyn's total compensation is reasonable compared to companies of similar size in the Swiss market.
Compensation vs Earnings: Insufficient data to compare Selwyn's compensation with company performance.
CEO
Selwyn Ho (53 yo)
2.3yrs
Tenure
€612,472
Compensation
Dr. Selwyn Ho, MBBS, serves as Chief Executive Officer & Chairman of the Executive Management Board at Medigene AG since July 25, 2022. He served as Chief Business Officer at Connect Biopharma Holdings Lim...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Chairman of Executive Management Board | 2.3yrs | €612.47k | 0.42% CHF 122.0k | |
| Chief Scientific Officer | 10.4yrs | €624.00k | no data | |
| Co-Founder & Chairman Scientific Advisory Board | no data | €20.00k | no data | |
| Chief Financial Officer | no data | no data | no data | |
| Vice President of Investor Relations & Corporate Communications | 1.6yrs | no data | no data | |
| VP and Head of Clinical Research & Development | 1.6yrs | no data | no data |
1.9yrs
Average Tenure
Experienced Management: MDG1's management team is not considered experienced ( 1.9 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder & Chairman Scientific Advisory Board | 7.2yrs | €20.00k | no data | |
| Independent Member of the Supervisory Board | 3.8yrs | €21.00k | no data | |
| Independent Deputy Chairwomen of the Supervisory Board | 8.2yrs | €36.00k | no data | |
| Independent Chairman of the Supervisory Board | 7.4yrs | €46.00k | no data | |
| Independent Member of the Supervisory Board | 7.4yrs | €24.00k | no data | |
| Independent Member of the Supervisory Board | 6.4yrs | €30.00k | 0.071% CHF 20.7k | |
| Member of Scientific Advisory Board | 7.2yrs | no data | no data | |
| Member of Scientific Advisory Board | 7.2yrs | no data | no data | |
| Member of Scientific Advisory Board | 7.2yrs | no data | no data | |
| Member of Scientific Advisory Board | 7.2yrs | no data | no data | |
| Member of Scientific Advisory Board | 7.2yrs | no data | no data |
7.2yrs
Average Tenure
68yo
Average Age
Experienced Board: MDG1's board of directors are considered experienced (7.2 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/10/06 16:49 |
| End of Day Share Price | 2024/07/09 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Medigene AG is covered by 10 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Xian Deng | Berenberg |
| Gary Waanders | Bryan Garnier & Co |
| Christian Orquera | First Berlin Equity Research GmbH |